TerminatedPHASE1, PHASE2NCT03922100
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Studying Acute myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nerviano Medical Sciences
- Principal Investigator
- Alessandro Rambaldi, MDASST Papa Giovanni XXIII
- Intervention
- NMS-03592088(drug)
- Enrollment
- 63 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (11)
- Centre Hospitalier du Mans, Le Mans, France
- Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes, France
- CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque, Pessac, France
- Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
- ASST Papa Giovanni XXIII, Bergamo, BG, Italy
- ASST Grande Ospedale Metropolitano Niguarda, Milan, MI, Italy
- Istituto Clinico Humanitas, Rozzano, MI, Italy
- Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy
- ASST Spedali Civili di Brescia, Brescia, Italy
- Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy
- Hospital Universitari i Politècnic La Fe, Valencia, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03922100 on ClinicalTrials.govOther trials for Acute myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasCrossbow Therapeutics, Inc.
- RECRUITINGPHASE2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny
- RECRUITINGPHASE2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong
- RECRUITINGPHASE1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE1NCT05636514Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSClinical Hub for Interventional Research (CHOIR)
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center